Related coverage linked through entity extraction aliases.
Aug 19, 2026
Silo Pharma received a European patent grant and a Japan patent allowance for SPC-15, its intranasal PTSD prevention candidate. The patents cover methods using serotonin 4 receptor agonists to prevent stress-induced psychiatric disorders.
Apr 07, 2026
Silo Pharma said the Japan Patent Office issued a Notice of Allowance for a patent application covering SPC-15, its intranasal PTSD therapeutic. The allowed application covers composition and method claims, with formal patent grant expected to follow.
Feb 17, 2026
Moleculin Biotech announced the Japan Patent Office has issued a notice of allowance for a patent covering proprietary methods for reconstituting liposomal Annamycin, strengthening the company's international intellectual property position.
Feb 14, 2026
Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.
